Core Insights - Medtronic reported quarterly earnings of $1.36 per share, exceeding the Zacks Consensus Estimate of $1.33 per share, but down from $1.39 per share a year ago, resulting in an earnings surprise of +2.07% [1] - The company achieved revenues of $9.02 billion for the quarter ended January 2026, surpassing the Zacks Consensus Estimate by 1.35% and up from $8.29 billion year-over-year [2] Earnings Performance - Medtronic has surpassed consensus EPS estimates in all four of the last quarters [2] - The company’s shares have increased by approximately 3.6% since the beginning of the year, contrasting with a 0.1% decline in the S&P 500 [3] Future Outlook - The future performance of Medtronic's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.68 on revenues of $9.6 billion, and for the current fiscal year, it is $5.64 on revenues of $36.04 billion [7] Industry Context - The Medical - Products industry, to which Medtronic belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Earnings Q3 FY26 | February 17, 2025 Contact: investor.relations@medtronic.com Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade polic ...

Medtronic said profit fell in its fiscal third quarter as costs rose and the company invested more money into the business, offsetting higher revenue. https://t.co/JolC87xCgB ...

Core Viewpoint - Medtronic reported a decline in profit during its fiscal third quarter due to rising costs and increased investments in the business, which countered the effects of higher revenue [1] Financial Performance - The company experienced a profit decrease in the fiscal third quarter, attributed to escalating costs and strategic investments [1] - Higher revenue was noted, but it was not sufficient to offset the increased expenses [1]

Medtronic plc (MDT) shares were down more than 5% in pre-market trading on Tuesday after the healthcare company reported lower third-quarter profit, primarily due to higher expenses.Net income fell to $1.143 billion, or $0.89 per share, from $1.294 billion, or $1.01 per share a year earlier. Adjusted earnings, which exclude one-time items, came in at $1.750 billion, or $1.36 per share.Operating profit decreased to $1.464 billion from $1.646 billion last year.The company's revenue for the period rose 8.7% t ...

Group 1 - Activist investor Jana Partners has acquired a stake in Fiserv and is urging the company to take actions to improve its declining share price [1] - Fiserv's shares increased by 6.5% in premarket trading following the news [1] - The company's stock has experienced a significant decline, dropping over 67% in 2025 [1]

Medtronic says it expects to take a $185 million hit from tariffs in the fiscal year. ...

Financial Performance - Medtronic reported Q3 FY26 revenue of $9.017 billion, an increase of 8.7% as reported and 6.0% organic, exceeding guidance by 50 basis points[2]. - GAAP diluted EPS for Q3 was $0.89, while non-GAAP diluted EPS was $1.36, three cents above the midpoint of guidance[2][8]. - The company reiterated its FY26 organic revenue growth guidance of approximately 5.5% and non-GAAP EPS guidance of $5.62 to $5.66[9]. - Net income attributable to Medtronic for the three months ended January 23, 2026, was $1,143 million, compared to $1,294 million in the same period in 2025, reflecting a decrease of 11.7%[39]. - Basic earnings per share for the three months ended January 23, 2026, were $0.89, down from $1.01 in the prior year[42]. - Non-GAAP net income attributable to Medtronic for the nine months ended January 23, 2026, was $5,122 million, compared to $4,999 million in the same period of 2025[49]. - The company reported net income of $3,578 million for the nine months ended January 23, 2026, compared to $3,630 million for the same period in the previous year[66]. Revenue Breakdown - The Cardiovascular portfolio generated $3.457 billion in revenue, reflecting a 13.8% increase as reported and 10.6% organic growth[4]. - Diabetes revenue increased by 8.3%, with double-digit growth in international markets contributing significantly[5][11]. - The Neuroscience portfolio revenue reached $2.558 billion, marking a 4.1% increase reported and 2.5% organic growth[11]. - U.S. revenue for the third quarter of FY26 was $4,493 million, representing a 6.0% growth compared to $4,237 million in FY25[30]. - International revenue for FY26 Q3 was $4,524 million, an 11.6% increase from $4,055 million in FY25 Q3[34]. - Total reportable segments for the year-to-date in FY26 reached $13,234 million, a 11.2% increase from $11,986 million in FY25[34]. Segment Performance - Cardiac Ablation Solutions revenue surged 80%, with a remarkable 137% growth in the U.S., driven by the pulsed field ablation portfolio[2][4]. - Cardiovascular segment reported $1,589 million in revenue for FY26 Q3, a 13.1% increase from $1,405 million in FY25 Q3[30]. - Cardiac Rhythm & Heart Failure segment grew by 23.0% to $953 million in FY26 Q3, up from $775 million in FY25 Q3[30]. - The Neuroscience segment reported a revenue of $1,709 million in FY26 Q3, a slight increase of 1.2% from $1,689 million in FY25 Q3[30]. - Specialty Therapies segment revenue decreased by 4.0% to $402 million in FY26 Q3 compared to $419 million in FY25 Q3[30]. Expenses and Profitability - Gross margin for the three months ended January 23, 2026, was 63.8%, down from 66.5% in the prior year[42]. - Operating profit for the nine months ended January 23, 2026, was $4,594 million, representing a 1.7% increase from $4,519 million in the same period of 2025[49]. - Non-GAAP operating profit for the three months ended January 23, 2026, was $2,177 million, with an operating profit margin of 24.1%[42]. - Research and development expenses for the three months ended January 23, 2026, were $722 million, an increase from $675 million in the same period of 2025[39]. - The effective tax rate for the three months ended January 23, 2026, was 18.1%, compared to 15.4% in the prior year[42]. Cash Flow and Investments - For the nine months ended January 23, 2026, net cash provided by operating activities was $4,757 million, compared to $4,516 million for the same period in the previous year[62]. - Free cash flow for the nine months ended January 23, 2026, was $3,341 million, up from $3,116 million in the prior year[62]. - The company incurred $1,416 million in additions to property, plant, and equipment for the nine months ended January 23, 2026[66]. - The company reported a net cash used in investing activities of $2,017 million for the nine months ended January 23, 2026[66]. - The company’s total liabilities decreased by $1,072 million, resulting in cash and cash equivalents at the end of the period of $1,147 million[66]. - The company’s dividends to shareholders for the nine months ended January 23, 2026, were $2,731 million, compared to $2,692 million in the previous year[66]. Strategic Developments - Medtronic secured U.S. FDA clearance for the Hugo™ robotic-assisted surgery system and the Stealth AXiS™ Surgical System for spinal procedures[5]. - Medtronic executed two key M&A transactions in the quarter, acquiring CathWorks and Anteris, enhancing its market position[5][12]. - The company experienced a foreign exchange benefit of $242 million across its segments, positively impacting overall revenue[6]. - The company recognized $30 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio[43]. - The company recognized $121 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio[50]. - The company adjusted $656 million in revenue for the nine months ended January 23, 2026, including $512 million from favorable currency impacts[28]. - The total revenue adjustments for the three months ended January 23, 2026, amounted to $275 million, including $242 million from favorable currency impacts[28].

Medtronic beats quarterly profit estimates on robust demand for heart devices | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A general view of the logo of Medtronic, a healthcare technology and pharmaceutical company, at their plant, in Galway, Ireland, April 11, 2025. REUTERS/Clodagh Kilcoyne/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Medtronic Inc]Follow[Abbott Laboratories]Follow[Dexcom Inc]FollowShow more ...

not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial ...